Beijing Danatlas Pharmaceutical Technology

Beijing Danatlas Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on addressing significant unmet medical needs in metabolic diseases and oncology. Its lead candidate, DA-011, is a potent and selective URAT1 inhibitor currently undergoing Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, Danatlas is advancing DA-052, a dual TLR7/8 agonist, into clinical development for the treatment of solid tumors. Supported by prominent venture capital firms, the company leverages its proprietary drug discovery platform to build a diverse pipeline of candidates targeting immune-oncology and inflammatory pathways.